BGB-B167

DRUG2 trials

Sponsors

BeiGene

Conditions

Solid TumorSolid Tumors

Phase 1

Safety, Pharmacokinetics, and Antitumor Activity of BGB-B167 Alone and in Combination With Tislelizumab (BGB-A317) in Participants With Advanced Solid Tumors

TerminatedNCT05494762

BeiGeneSolid Tumor

Start: 2022-08-25End: 2025-02-24Updated: 2025-05-01

Safety, Pharmacokinetics and Antitumor Activity of BGB-B167 Alone and in Combination With Tislelizumab in Participants With Solid Tumors in Chinese Participants

WithdrawnNCT05644626

BeiGeneSolid Tumors

Start: 2024-03-31End: 2025-08-31Updated: 2023-11-29

Related Papers

First-in-human, phase 1a, dose escalation study of BGB-B167, a CEA x 4-1BB bispecific antibody, as monotherapy or combined with tislelizumab (anti-PD-1), in patients with selected advanced or metastatic solid tumors.

Journal of Clinical Oncology2025-01-272 citations